Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600196 Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

Closed 04-30 15:00:00

24.89

-0.39

-1.54%

High25.27	Low24.89	Vol27.64M
Open25.27	D1 Closing25.28	Amplitude1.50%
Mkt Cap66.46B	Tradable Cap52.72B	Total Shares2.67B
T/O690.00M	T/O Rate1.31%	Tradable Shares2.12B
P/B1.35	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.","latestPrice":24.89,"timestamp":1777532400000,"preClose":25.28,"halted":0,"volume":27640568,"delay":0,"changeRate":-0.0154,"floatShares":2118000000,"shares":2670000000,"eps":1.3019,"marketStatus":"Closed","change":-0.39,"latestTime":"04-30 15:00:00","open":25.27,"high":25.27,"low":24.89,"amount":690000000,"amplitude":0.015,"askPrice":24.9,"askSize":514,"bidPrice":24.89,"bidSize":415,"shortable":0,"etf":0,"ttmEps":1.3019,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1778031000000},"marketStatusCode":5,"adr":0,"adjPreClose":25.28,"symbolType":"stock","openAndCloseTimeList":[[1777512600000,1777519800000],[1777525200000,1777532400000]],"highLimit":27.81,"lowLimit":22.75,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.35,"roa":"--","peRate":19.118212,"roe":"1.78%","epsLYR":1.27,"committee":0.491876,"marketValue":66467000000,"turnoverRate":0.013,"status":1,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"FOSUN PHARMA","latestPrice":19.11,"timestamp":1777536493003,"preClose":19.58,"halted":0,"volume":3528235,"delay":0,"premium":"-33.03"},"floatMarketCap":52729000000},"requestUrl":"/m/hq/s/600196/wiki","defaultTab":"wiki","newsList":[{"id":"2631681011","title":"Fosun Pharma unit Yaopharma wins China approval for sodium nitroprusside injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2631681011","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631681011?lang=en_us&edition=fundamental","pubTime":"2026-04-30 17:34","pubTimestamp":1777541671,"startTime":"0","endTime":"0","summary":"Fosun Pharma unit Yaopharma secured China marketing clearance for Sodium Nitroprusside Injection.Yaopharma listed strength at 2ml:50mg; registration category chemicals category 3.Fosun Pharma reported R&D spending of about RMB 3.21 million on drug as of March 2026.China 2025 sales for sodium nitroprusside injections totaled about RMB 112 million, based on IQVIA CHPA data.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 30, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL3bPW73:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0130103400.USD","BK0188","LU1989764748.USD","BK4588","LU0648000940.SGD","LU1989764664.SGD","BK4121","BK4585","BK0012","LU0477156797.USD","BK0175","BK0028","BK0183","LU0528227936.USD","LU0477156953.USD","LU0130518102.USD","00656","LU0648001328.SGD","LU1201861165.SGD","LU0130102774.USD","BK0187","LU1791710400.SGD","BK1230","BK0096","BK0196","LU0130517989.USD","BK0239","LU1261432733.SGD","LU1791710582.SGD","600196","BK4530","LU0882574055.USD","LU0980610538.SGD","BK0060","LU0198837287.USD","LU1201861249.SGD","IQV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631681015","title":"Shanghai Fosun Pharma -  Drug Registration Application for Sodium Nitroprusside Injection Approved by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2631681015","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631681015?lang=en_us&edition=fundamental","pubTime":"2026-04-30 17:34","pubTimestamp":1777541659,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nFWN41D0PL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","600196","02196","BK0239","BK0060","BK0012","BK0187","BK1515","BK0183","BK0028","BK0096","BK0188","BK1593","BK0196","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174617856","title":"FOSUN PHARMA Subsidiary Receives Regulatory Approval for Sodium Nitroprusside Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1174617856","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174617856?lang=en_us&edition=fundamental","pubTime":"2026-04-30 16:30","pubTimestamp":1777537818,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (600196.SH) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently received approval from the National Medical Products Administration for the drug...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0183","BK0239","600196","BK1593","BK0196","BK0060","BK0096","BK0187","BK0175","BK1515","BK1191","BK0188","02196","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631557679","title":"Fosun Pharmaceutical Reports 14% Higher Profit in Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=2631557679","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631557679?lang=en_us&edition=fundamental","pubTime":"2026-04-29 12:27","pubTimestamp":1777436863,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  logged a 14% rise in its attributable profit for the first quarter of 2026 to 870.8 million yuan from 764.8 million yuan a year earlier, according to a Hong Kong bourse filing Tuesday.The pharmaceutical company's Hong Kong shares fell nearly 2% in late morning trade Wednesday.Earnings per share were 0.33 yuan, compared with 0.29 yuan in the prior year.Operating revenue gained nearly 7% to 10.1 billion yuan, figures showed.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0012","BK1191","BK0060","BK0196","BK0175","BK0187","BK0183","BK0096","BK1593","600196","BK0239","BK0028","02196","BK0188","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630586568","title":"Press Release: Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution","url":"https://stock-news.laohu8.com/highlight/detail?id=2630586568","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630586568?lang=en_us&edition=fundamental","pubTime":"2026-04-28 22:54","pubTimestamp":1777388040,"startTime":"0","endTime":"0","summary":"SHANGHAI, April 28, 2026 /PRNewswire/ -- On 28 April, Fosun Pharma  announced its results for the first quarter of 2026 . During the reporting period, the Company achieved a total revenue of RMB 10,073 million, representing a year-on-year increase of 6.93%. Regarding R&D investment, the Company firmly implemented its innovation transformation strategy. During the reporting period, the R&D expenditure increased to RMB 897 million, increased by 1.59% YoY. While increasing the R&D intensity, the Company maintained a positive growth trend in profit. Net profit attributable to shareholders of the list company after deducting extraordinary gain or loss was RMB 501 million, up 21.96% year-on-year. Net profit attributable to shareholders of the listed company was RMB 871 million, increased by 13.87% YoY. Net cash flows generated from operating activities was RMB 1,149 million, up 8.8% YoY.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4008","BK0175","BK1593","BK4551","BK0183","AGIX","BK0187","BK0028","BK1515","600196","BK0096","BK4023","BK4585","02196","BK4096","BK4528","BK0239","TM","AIYY","BK0188","BK4588","AI","BK4604","BK4587","BK4543","BK0060","03160","BK4555","R","PN","BK4232","AIPO","BK0012","ARTY","BK4500","BK4099","BK1191","CHAT","BK4022","ALK","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630326309","title":"Fosun Pharma, Arcera Life Sciences sign MoU for long-term strategic collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2630326309","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630326309?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:44","pubTimestamp":1777376643,"startTime":"0","endTime":"0","summary":"Fosun Pharma signed memorandum of understanding with Abu Dhabi-based Arcera Life Sciences to set long-term strategic collaboration on licensing, technology development, neuroscience innovation.Partnership targets regional and global licensing of Fosun Pharma assets, initially focusing on oncology, neuroscience, rare diseases, cardiometabolic disease.Neuroscience work will prioritize neurodegenerative diseases, including Alzheimer’s programs, as partners seek to expand access in Middle East and other markets.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via PR Newswire  on April 28, 2026, and is solely responsible for the informatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL60Y3nw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","600196","BK0187","BK0188","BK0060","BK0175","BK0012","BK1230","BK0239","00656","BK0096","BK0183","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630130622","title":"Arcera Life Sciences and Fosun Pharma Launch Long-Term Collaboration Framework","url":"https://stock-news.laohu8.com/highlight/detail?id=2630130622","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630130622?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:38","pubTimestamp":1777376301,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nTUA92B36C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK0060","BK0175","BK0196","BK0012","BK0096","BK0183","BK0188","BK0028","600196","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630376455","title":"BRIEF-Shanghai Fosun Pharmaceutical Group Q1 Net Profit Up 13.9% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2630376455","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630376455?lang=en_us&edition=fundamental","pubTime":"2026-04-28 16:43","pubTimestamp":1777365823,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharmaceutical Group Q1 Net Profit Up 13.9% Y/YApril 28 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:Q1 NET PROFIT UP 13.9% Y/YSource textFurther company coverage: 600196.SS (Reporting by Beijing Newsroom) ((Shi.Bu@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nL4N41B0WA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0196","BK0028","BK0175","BK0183","600196","BK0188","BK0096","BK0187","BK0012","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629048133","title":"Sisram says Fosun unit FPI completes controlling shareholder reorganization, holds 71.4% stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2629048133","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629048133?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:14","pubTimestamp":1776856480,"startTime":"0","endTime":"0","summary":"Sisram Medical completed controlling-shareholder reorganization involving Fosun Pharma subsidiaries.FPI took over Ample Up and Chindex stakes totaling about 71.4% of Sisram shares.FPI now holds 334,504,800 Sisram shares as of April 22, 2026.Fosun Pharma indirect equity interest in Sisram remained unchanged.Securities and Futures Commission granted waiver from mandatory general offer obligation tied to transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL2mRvd9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00656","BK0183","BK0196","BK0187","01696","600196","BK1585","BK0175","BK0239","BK0012","BK0096","BK0060","BK0188","BK1230","BK0028","BK1100","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187485185","title":"Morgan Stanley Raises Fosun Pharma's Revenue Forecast, Sets HK$32 Target with \"Overweight\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1187485185","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187485185?lang=en_us&edition=fundamental","pubTime":"2026-04-22 17:00","pubTimestamp":1776848428,"startTime":"0","endTime":"0","summary":"Morgan Stanley has released a research report indicating an upward revision of FOSUN PHARMA's (02196) revenue forecast for 2026 to 2028 by 3%. This adjustment is based on increased sales of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0060","BK0175","BK0196","BK0187","600196","BK0239","BK1191","02196","BK1515","BK0183","BK0012","EWH","BK1593","BK0028","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629089962","title":"Fosun Pharma releases 2025 ESG and Sustainability Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2629089962","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629089962?lang=en_us&edition=fundamental","pubTime":"2026-04-21 16:45","pubTimestamp":1776761153,"startTime":"0","endTime":"0","summary":"Fosun Pharma released its 2025 ESG and Sustainability Report, highlighting a higher MSCI ESG rating of AA.Environmental protection spending reached nearly RMB 80 million.Photovoltaic power generation totaled 31 million kWh, cutting 1,654 tons of CO2e.Green electricity procurement rose to 46 million kWh, including renewable electricity purchases, hydropower.Energy-saving actions reduced carbon emissions by 11,811 tons of CO2e, lowering energy intensity 6.8% to 1.717 GJ per RMB 10,000 revenue.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 21, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL4DldK2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0196","BK0096","BK0188","00656","BK0175","BK0028","600196","BK0187","BK0060","BK0012","BK1230","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629089867","title":"Fosun Pharma publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2629089867","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629089867?lang=en_us&edition=fundamental","pubTime":"2026-04-21 16:37","pubTimestamp":1776760651,"startTime":"0","endTime":"0","summary":"Fosun Pharma annual report for 2025 flagged continued shift toward an innovation-led model, with faster international expansion and wider use of AI across R&D and commercialization.Innovation drugs revenue rose 29.6% to RMB 9.9 billion, lifting mix to 23.8% of group revenue.Overseas revenue increased 14.9% to RMB 13 billion, taking share of total revenue to 31.3%.Pipeline progress included launches for Fu Mai Ning and Fu Tuo Ning in China, with serplulimab gaining European Commission clearance for extensive-stage small cell lung cancer.R&D spending totaled RMB 5.9 billion, with 72.8% directed to innovation-drug programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original conten","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL5Z7pDv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0028","BK1230","BK0096","BK0196","BK0012","600196","BK0175","BK0183","BK0187","BK0188","BK0060","00656"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627654447","title":"BRIEF-Shanghai Fosun Pharma Unit Received Approval From NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2627654447","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627654447?lang=en_us&edition=fundamental","pubTime":"2026-04-14 22:47","pubTimestamp":1776178026,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma Unit Received Approval From NMPAApril 14 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:UNIT RECEIVED APPROVAL FROM NMPA FOR PHASE I/II CLINICAL TRIAL OF FKC289 INJECTIONFurther company coverage: 600196.SS ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40X017:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0060","BK1191","BK0188","BK0196","02196","BK0012","BK1593","BK0187","BK0096","BK0183","BK1515","BK0175","600196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627417772","title":"Fosun Pharma Unit Gets China Nod for Amyloidosis Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627417772","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627417772?lang=en_us&edition=fundamental","pubTime":"2026-04-14 18:42","pubTimestamp":1776163326,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  unit Fosun Kairos  Biological Technology obtained approval for a phase I/II clinical trial of FKC289 injection from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The drug will be tested for the treatment of primary light chain amyloidosis and membranous nephropathy.The subsidiary will begin the trial once conditions are met.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02196","BK0060","BK0196","BK0012","BK0188","BK1593","BK0239","BK0028","BK1191","BK0183","BK1515","600196","BK0187","BK0096","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627414768","title":"Fosun Kairos wins China nod for Phase I/II trial of FKC289 CAR-T injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2627414768","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627414768?lang=en_us&edition=fundamental","pubTime":"2026-04-14 17:59","pubTimestamp":1776160770,"startTime":"0","endTime":"0","summary":"Fosun Kairos, unit of Fosun Pharma, secured China regulator clearance for Phase I/II clinical trials of FKC289 injection.Trials target relapsed or refractory primary light chain amyloidosis, relapsed or refractory membranous nephropathy.FKC289 is dual-target CAR-T therapy aimed at BCMA, CD19.Fosun Pharma R&D spending on FKC289 totaled about RMB 59 million as of March 2026.Fosun Pharma said no therapies using same molecular mechanism have been marketed globally as of April 14.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 14, 2026, and is sol","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDLbGc62m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0175","BK0196","BK0188","BK0012","BK1230","BK0028","00656","BK0060","600196","BK0187","BK0239","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627271414","title":"Shanghai Fosun Pharma - Unit Received Approval From Nmpa for Phase I/Ii Clinical Trial of Fkc289 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2627271414","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627271414?lang=en_us&edition=fundamental","pubTime":"2026-04-14 17:58","pubTimestamp":1776160733,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40X017:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK1593","BK0183","BK0196","BK1191","600196","02196","BK0028","BK0096","BK0012","BK0187","BK0175","BK0188","BK1515","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125283237","title":"FOSUN PHARMA Subsidiary Receives Approval for Phase I Trial of HLX05-N Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1125283237","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125283237?lang=en_us&edition=fundamental","pubTime":"2026-04-14 17:10","pubTimestamp":1776157835,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (600196.SH) has announced that its subsidiary, Shanghai Henlius Biotech, along with its controlled subsidiaries, recently obtained approval from the National Medical Products...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0096","BK0196","BK0187","600196","BK0239","BK1593","BK0188","BK0060","BK1515","BK0175","BK0028","02196","BK1191","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626789199","title":"BRIEF-Shanghai Fosun Pharma Unit's Drug Registration Application For Flurbiprofen Axetil Injection Approved By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2626789199","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626789199?lang=en_us&edition=fundamental","pubTime":"2026-04-10 18:34","pubTimestamp":1775817257,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma Unit's Drug Registration Application For Flurbiprofen Axetil Injection Approved By NMPAApril 10  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:UNIT'S DRUG REGISTRATION APPLICATION FOR FLURBIPROFEN AXETIL INJECTION APPROVED BY NMPAFurther company coverage: 600196.SS ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nFWN40T03O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196","BK1515","BK0187","600196","BK0183","BK0028","BK0096","BK0060","BK1191","BK0239","BK1593","BK0012","BK0188","BK0196","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173461200","title":"FOSUN PHARMA's Flurbiprofen Axetil Injection Receives Marketing Authorization","url":"https://stock-news.laohu8.com/highlight/detail?id=1173461200","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173461200?lang=en_us&edition=fundamental","pubTime":"2026-04-10 17:44","pubTimestamp":1775814265,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently obtained approval from the National Medical Products Administration for the drug...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196","BK0060","BK0187","BK0096","BK1191","BK0028","BK0012","BK0175","BK0196","BK0188","BK1515","BK1593","BK0183","BK0239","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626195105","title":"Shanghai Fosun Pharma - Unit's Drug Registration Application for Flurbiprofen Axetil Injection Approved by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2626195105","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626195105?lang=en_us&edition=fundamental","pubTime":"2026-04-10 17:38","pubTimestamp":1775813895,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nFWN40T03O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["600196","BK0239","BK1191","BK0196","BK0183","BK0012","BK0096","02196","BK0060","BK1593","BK0187","BK1515","BK0028","BK0188","BK0175"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","stockEarnings":[{"period":"1week","weight":-0.0121},{"period":"1month","weight":-0.0518},{"period":"3month","weight":-0.0678},{"period":"6month","weight":-0.1342},{"period":"1year","weight":0.0736},{"period":"ytd","weight":-0.0457}],"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"267042万元","compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.047},{"period":"3month","weight":-0.0121},{"period":"6month","weight":0.0386},{"period":"1year","weight":0.2498},{"period":"ytd","weight":0.0349}],"survey":"　　上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。根据工信部中国医药工业信息中心颁布的“2024年度中国医药工业百强企业榜单”，本集团位列第5位。此外，在ESG方面，复星医药于报告期内荣登2025《财富》ESG影响力榜单，成为唯一入选该榜单的中国医药企业。根据MSCI于2025年7月公布的ESG年度评级结果，本集团MSCIESG评级提升至AA级。在AI领域，复星医药凭借自主研发的PharmAID医药智能平台荣获福布斯“2025中国人工智能科技创新场景应用企业TOP10”。","serverTime":1777560437589,"listedPrice":7.15,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.,600196,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎国际,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股价,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股市,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票价格,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票交易,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票购买,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction